Hyaluronic acid (HA) is found in high concentrations in cartilage and synovial fluid, and is an important component of the extracellular matrixes -exerting joint lubrication and buffering actions thanks to its viscoelastic properties. The present study examines the scientific evidence found in the current literature on the usefulness of the intraarticular injection of HA in patients with temporomandibular dysfunction. A literature search was made up until May 2008 in the following databases: PubMed / MEDLINE. Of the articles found in the literature, the present review included 18 relevant studies on the application of HA in the temporomandibular joint (TMJ). The quality, level of evidence and strength of recommendation of the articles was evaluated based on the "Strength of Recommendation Taxonomy" criteria. It is concluded that type A level of recommendation exists in favor of the intraarticular injection of HA in dysfunction of the TMJ. However, further studies are needed to establish the true therapeutic effects and to identify the best dosing regimen.
Introduction
Hyaluronic acid (HA) is a linear, hydrophilic, polyanionic high molecular weight polysaccharide exclusively composed of repeated disaccharide units of glucuronic acid and N-acetylglucosamine. HA is a natural component of joint synovial fluid, and is also found in the extracellular matrix of connective tissue (1, 2) . The authors that make use of HA consider that the intraarticular injection of HA in patients with temporomandibular joint dysfunction (TMJD) improves function and lessens pain. The excellent mechanical and metabolic properties of the molecule define it as an ideal treatment for inflammatory problems of the temporomandibular joint (TMJ) (3, 4) . The mechanical action of HA is based on joint lubrication and consequently lessened joint wear secondary to adhesions, with a reduction in friction within the intraarticular space. HA also reduces the levels of inflammatory mediators, thus contributing to afford relief from joint pain (1,2, 4-7). Its metabolic activity in turn involves the facilitation of nutrition in avascular zones of the joint disc and cartilage. HA acts in the combination of glycosaminoglycans to form proteoglycan, which under pathological conditions disintegrates and disperses within the synovial cavity (4) (5) (6) (7) (8) . Despite the fact that its half-life is about 13 hours, the intraarticular application of HA offers persistent beneficial effects (2, 3, 7) . The excellent lubricating properties of the molecule may offer a conservative, safe and effective alternative to the existing treatments which offer less satisfactory results in application to certain joint dysfunctions (1,2, 4-7). The present study was therefore designed to determine whether the level of scientific evidence found in the literature justifies the recommendation of intraarticular HA injection in the clinical management of TMJD.
Material and Methods
A MEDLINE search was made covering the period between 1966 and 2008, applying synonyms and Medical Subject Headings (MeSH) first for temporomandibular joint dysfunction (TMJD) and then for hyaluronic acid (HA), with the purpose of generating a principal series of articles. Posteriorly, the identified literature was limited to human studies and articles published in English. Both search strategies were in turn combined by means of an "AND" boolean operator, thus crossing the articles on TMJD and HA. Two of the authors analyzed the identified articles to determine whether they were pertinent to the study, with exclusion of those papers considered to be irrelevant. Then, separately and based on the SORT (Strength of Recommendation Taxonomy) criteria, the two authors stratified the studies according to their level of scientific evidence (9). This was followed by correlation of the results, and any observed discrepancies were subjected to discussion. If no consensus could be reached regarding the level of scientific evidence of a given article, another author was included in the discussion. Posteriorly, and according to the established level of evidence of the articles, a level of recommendation (in favor or against) was issued on the use of HA for the treatment of TMJD.
Results
The MEDLINE search yielded 10,000 articles for TMJD and 5956 for HA. As mentioned above, both search strategies were crossed to yield a pool of 28 articles. The article abstracts were then examined to establish whether the publications were relevant to the study subject. A total of 18 relevant articles were identified. These were critically reviewed and classified according to their level of scientific evidence. Posteriorly, and according to the results obtained by these articles, a level of recommendation (in favor or against) was established regarding the intraarticular injection of HA (9) .
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The analysis yielded 9 articles with level of evidence 1 (1-3, 5,8, 10-13), and 7 with level of evidence 2 (4,6,7, 14-17). The 9 publications classified as being of high quality were randomized double-blind studies with adequate sample sizes, parallel groups, statistical analysis and adequate follow-up. On the other hand, the 7 publications classified as presenting limited quality evidence were non-randomized studies with an adequate sample size, parallel groups, statistical analysis and adequate follow-up. Based on these publications we established strength of recommendation A in favor of the use of HA in the treatment TMJD: reducible disc displacement (RDD), non-reducible disc displacement (NRDD), and other degenerative joint diseases. The characteristics of the reviewed studies allowed us to include them in groups according to the treatments prescribed. Three types of comparisons were identified: HA versus placebo, HA versus glucocorticoids (CO), and arthroscopy or arthrocentesis combined with HA versus arthroscopy or arthrocentesis with placebo (Table 1).
Discussion
Hyaluronic acid (HA) is the principal natural component of synovial fluid. Although it has great importance in joint lubrication, the mechanism by which HA affords improvement in joint disease is not entirely clear. In the relevant studies found in the literature, HA was compared with placebo, glucocorticoids (CO) and combined with other surgical treatments (arthroscopy or arthrocentesis). The Helkimo clinical dysfunction index and subjective symptoms of mandibular function, pain and joint sounds as measured by multiple response questionnaires and a visual analog scale (VAS) provided an indication as to the positive or negative recommendation of treatment with HA. Comparing hyaluronic acid with placebo, Bertolami et al. (3) designed a multicenter study with a duration of 6 months in which they examined the effects of the intraarticular injection of HA in 80 patients (experimental group): 35 with reducible disc displacement (RDD), 8 with non-reducible disc displacement (NRDD), and 37 with degenerative joint disease (DJD). The placebo group included 41 patients: 15 with RDD, 6 with NRDD and 20 with DJD. For measuring joint dysfunction and the course after treatment, the authors used two indexes proposed by Helkimo: the anamnesis index for describing patient perception of the clinical problem and treatment efficacy, and the clinical dysfunction index for determining the functional condition of the joint. The results showed significant improvement of these indexes in the RDD patients treated with HA versus the placebo group. In patients with NRDD and DJD, improvement was seen in both groups, though without statistically significant differences between them. clinical dysfunction index. The end symptoms, compared with the situation before treatment, had improved in 10 of the 14 patients treated with HA, and in 9 of the 13 patients of the placebo group. The mean symptoms reduction on the VAS was 11 mm in the HA group and 8 mm in the placebo group, while the clinical dysfunction index showed a mean 5-point reduction in both groups. This is the only high quality study in which HA is compared with placebo in patients with rheumatoid arthritis (10). The results yielded type A recommendation that is neither in favor nor against the intraarticular injection of HA in the treatment of this type of temporomandibular disorder.
Comparison has also been made of the effect of HA versus glucocorticoids (CO). Kopp et al. (10) used the intraarticular injection of HA or CO in patients with TMJD refractory to conservative management. The symptoms were evaluated by the clinical dysfunction index, and by a 10-item questionnaire including the assessment of TMJ pain and pain in different zones of the face, difficulty opening the mouth, joint sounds, the duration of symptoms, and pain in other joints. The authors recorded improvement in both groups, with symptoms remission in 13 of the 18 patients treated with HA and in 9 of the 15 patients treated with CO after four weeks of follow-up. In another similar study by the same authors (5) and involving two years of follow-up, similar improvement was recorded for both types of treatment (HA and CO) according to the clinical dysfunction index. Nevertheless, Bjørnland et al. (12) considered that HA injections are more effective than CO in combating the intensity of pain, and that patients only presenting TMJ pain (without added myofascial pain) are the best candidates for this type of treatment. Regardless of whether HA or CO is injected, we at least can be sure that there will be no bone structural changes, as evidenced by Møystad et al. (13) , in their study of 36 patients with osteoarthritis in both TMJs. Two studies (5,10) evaluated a total of 74 patients with TMJD assigned randomly and on a blind basis to either HA (32 cases) or CO (29 cases). The results showed HA efficacy in securing remission of the symptoms of TMJD to be similar to that recorded in the CO group with no statistically significant differences between the two treatments in terms of oral opening and muscle or joint pain. Given the high quality of these studies, type A recommendation can be assumed, and the positive effects of both treatments over the short and long term are favorable to both the intraarticular application of HA and the use of CO in the treatment of TMJD. (8) .
Based on the evidence found in the literature, we consider that a multicenter, randomized, placebo-controlled double-blind study with a sufficiently large patient sample, well defined TMJD groups and the use of objective variables is absolutely necessary in order to establish the true therapeutic effects of the intraarticular injection of HA in patients with TMJD, and to define the best posology.
